SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $3.54 million as of 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2025-02-26
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $3.54M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $3.52M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.49M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2024-12-31 | $3.54M 10-K · filed 2025-02-26 |
| 2023-12-31 | $3.52M 10-K · filed 2025-02-26 |
| 2022-12-31 | $1.49M 10-K/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |